TC Biopharm Q1 2024 Earnings Report $0.28 -0.09 (-23.61%) As of 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast TC Biopharm EPS ResultsActual EPS-$22.40Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATC Biopharm Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATC Biopharm Announcement DetailsQuarterQ1 2024Date5/15/2024TimeN/AConference Call ResourcesTCBP Earnings History TC Biopharm Earnings HeadlinesTCBP to Implement ADS Ratio ChangeFebruary 5 at 12:00 PM | prnewswire.comTCBP Announces H5N1 Proof of Concept Studies IntentionJanuary 15, 2025 | prnewswire.comBuy these stocks before DOGE movesJust a few days after the inauguration, my firm issued an urgent and very specific warning about Donald Trump and Elon Musk's real agenda... Put simply, we claimed that Elon had secured himself a role within the administration to oversee the rollout of powerful new AI technology. More than that... we predicted the shortlist of tech firms involved in the rollout could create enormous wealth, starting immediately.February 5, 2025 | Altimetry (Ad)TCBP to Present at Sequire Investor Summit 2025January 13, 2025 | prnewswire.comTC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-ComplianceJanuary 8, 2025 | tipranks.comTC BioPharm: TCBP Trading Continues Unabated on Nasdaq Stock ExchangeJanuary 7, 2025 | finanznachrichten.deSee More TC Biopharm Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TC Biopharm? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TC Biopharm and other key companies, straight to your email. Email Address About TC BiopharmTC Biopharm (NASDAQ:TCBP), a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.View TC Biopharm ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Earnings Miss? Amgen’s Dividend Still a Bright SpotPalantir Stock Surges After Blockbuster Earnings: What's Next?Atlassian: Upside Still in Play After Impressive Earnings SpikeWhy Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After Earnings Upcoming Earnings AstraZeneca (2/6/2025)Fortinet (2/6/2025)Amazon.com (2/6/2025)Linde (2/6/2025)Sumitomo Mitsui Financial Group (2/6/2025)ING Groep (2/6/2025)ConocoPhillips (2/6/2025)KKR & Co. Inc. (2/6/2025)Intercontinental Exchange (2/6/2025)Thomson Reuters (2/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
